At Minerve Pharmaceuticals, we are redefining the treatment of neurodegenerative diseases through innovation and science.
About Minerve Pharmaceuticals
Lighting the path to maintaining cognitive clarity
We focus on a critical mechanism linked to synapse loss and cognitive decline in conditions like Alzheimer’s and Multiple Sclerosis.
AI-Driven Drug Discovery:
Our platform accelerates the creation of first-in-class therapies to inhibit harmful synaptic pruning.
Strategic Regulatory Approach:
ILeveraging the FDA’s Model-Informed Drug Development Program for streamlined drug development.
Expert Leadership and Collaboration:
IA team of accomplished professionals supported by top-tier advisors and strategic partnerships.
We pioneer a revolutionary approach to treating neurodegenerative diseases by addressing harmful synaptic pruning, a process reactivated due to chronic brain inflammation. This innovation preserves synaptic function and protects cognitive health.
By combining cutting-edge drug development with strategic regulatory pathways, we tackle the unmet needs in CNS therapeutics. Supported by a world-class team and collaborations, Minerve Pharmaceuticals is poised to shape the future of neurodegenerative disease treatment and improve millions of lives globally.